Neomorph

Stub active Updated Apr 13, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Diego, California
Founded 2019
Latest Stage Series B
Total Raised $100M+
Website https://neomorph.com
Sector
biotech oncology drug-discovery

Investors

deerfield-management series-b (2026)
regeneron-ventures series-b (2026)
longwood-fund series-b (2026)
alexandria-venture-investments series-b (2026)

Founders

Phil Chamberlain Co-Founder, President & CEO

About

Neomorph is a San Diego-based biotechnology company developing molecular glue degraders to target previously undruggable proteins across oncology, cardiometabolic disease, rare disease, neurology, and immunology 1. The company’s lead program, NEO-811, induces targeted degradation of the ARNT (HIF-1β) protein and is currently in a Phase 1/2 clinical trial for locally advanced or metastatic clear cell renal cell carcinoma 1. Neomorph has a $1.64 billion collaboration with AbbVie for molecular glue discovery 2.

Funding History

Date Round Amount Lead Co-investors
2026-04-13 Series B $100M Deerfield Management Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources

  1. GlobeNewsWire, “Neomorph Announces Closing of $100 Million Series B Financing,” April 13, 2026. https://www.globenewswire.com/news-release/2026/04/13/3272523/0/en/Neomorph-Announces-Closing-of-100-Million-Series-B-Financing.html↩↩↩

  2. San Diego Business Journal, “Neomorph, AbbVie Ink $1.64B Collab,” accessed April 2026. https://www.sdbj.com/life-sciences/pharmaceuticals/neomorph-abbvie-ink-1-64b-collab/↩